14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
HRMY vs AVDL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Avadel Pharmaceuticals plc Ordinary Share (AVDL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). HRMY carries a Unified Composite Score of 67.1/100 (BUY) at $32.59 (5.4x Forward P/E, 22.2% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin).
Growth vs. Quality Trade-Off: HRMY earns the overall head-to-head edge with a stronger Unified Composite Score (67.1/100 BUY vs. AVDL 62.9/100 BUY) and 0.55β · 38% Vol risk profile, whereas AVDL leads top-line expansion (+54.9% YoY revenue growth, 0.07x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: HRMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HRMY vs AVDL. Trailing 12-month operating profitability (HRMY 22.2% vs AVDL 2.5%) and valuation multiples (HRMY 5.4x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ HRMY vs AVDL Key Questions & Quantitative Answers
As of Nov 20, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Avadel Pharmaceuticals plc Ordinary Share (AVDL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). HRMY carries a Unified Composite Score of 67.1/100 (BUY) at $32.59 (5.4x Forward P/E, 22.2% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin). Growth vs. Quality Trade-Off: HRMY earns the overall head-to-head edge with a stronger Unified Composite Score (67.1/100 BUY vs. AVDL 62.9/100 BUY) and 0.55β · 38% Vol risk profile, whereas AVDL leads top-line expansion (+54.9% YoY revenue growth, 0.07x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: HRMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AVDL leads the Growth & Scale pillar: HRMY posts +12.3% YoY revenue growth and -6.9% YoY earnings growth on $989M TTM revenue (74.0% gross margin, 22.2% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, HRMY generates $989M in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, HRMY deploys 51.8% of Rev ($512M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.
HRMY screens cheaper on headline valuation multiples. HRMY trades at 5.4x Forward P/E, 10.9x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (32.6% FCF margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HRMY (18.7% ROE) versus AVDL (-0.3% ROE) capital efficiency.
In options market volatility and institutional positioning, HRMY carries 72.4% implied volatility (11th %ile, Compressed (<25th %ile)), a 4.40x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.55β · 38% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.